Breadcrumb

David J. FitzGerald, Ph.D.

David J. FitzGerald, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
Laboratory of Molecular Biology

RESEARCH SUMMARY

My lab develops antibody-based therapeutics for treating cancer. Our approach is to use antibodies or antibody fragments to deliver toxins for the purpose of killing cancer cells. Antibody-toxin molecules are called "immunotoxins". When immunotoxin treatment is less than 100% effective, we then add chemotherapy of various kinds to enhance killing. Along with our collaborators, discovering the best combinations of chemotherapy and immunotoxin has been the main goal of the lab for the past several years. Several particular combinations are under investigation for use in the clinic to treat patients with various malignancies.

Areas of Expertise

1) antibodies 2) toxins 3) cancer therapeutics 4) cell biology 5) immunotoxins

Publications

Selected Key Publications

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up

Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, FitzGerald DJ, Santiago L, Gao G, Lanasa MC, Pastan I
Blood. 131(21): 2331-34, 2018. [ Journal Article ]

Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity

Pasetto M, Antignani A, Ormanoglu P, Buehler E, Guha R, Pastan I, Martin SE, FitzGerald DJ
Proc Natl Acad Sci U S A. 112(10): E1135-42, 2015. [ Journal Article ]

Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins

Antignani A, Mathews Griner L, Guha R, Simon N, Pasetto M, Keller J, Huang M, Angelus E, Pastan I, Ferrer M, FitzGerald DJ, Thomas CJ
PLoS One. 11(8): e0161415, 2016. [ Journal Article ]

Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts

Onda M, Ghoreschi K, Steward-Tharp S, Thomas C, O'Shea JJ, Pastan IH, FitzGerald DJ
J Immunol. 193(1): 48-55, 2014. [ Journal Article ]

ABT-737 promotes the dislocation of ER luminal proteins to the cytosol, including Pseudomonas exotoxin

Antignani A, Sarnovsky R, Fitzgerald DJ.
Mol. Cancer Ther. 13: 1655-63, 2014. [ Journal Article ]

Job Vacancies

There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.

Team

Staff Scientist
Antonella Antignani, Ph.D.
Postdoctoral Fellow (Visiting)
Maria Bilotta, Ph.D.
Postdoctoral Fellow (Visiting)
Eric Chun Hei Ho, Ph.D.
Postbaccalaureate Fellow (CRTA)
Rong Qiu
Research Biologist
Robert Sarnovsky